MigraineActive ingredient
Rimegepant
CGRP receptor antagonist (gepant)1 FDA label read
Rimegepant is sold as Nurtec ODT and holds a position no other label in this category has: it is approved both for the acute treatment of a migraine attack and for the preventive treatment of episodic migraine. Same tablet, two indications, two different dosing schedules in one document.
Highlights of the labels
- Nurtec ODT
- Acute treatment of migraine, and prevention of episodic migrainecovers migraine
- Supply
- Prescription only
- Generic
- None approved
- Boxed warning
- None in these labels
Brands and what each one is approved for
One active ingredient can hold several separate FDA approvals. They are different documents with different approved uses, and mixing them up is the most common mistake made about these medications.
| Brand | What its label approves | Supply | Label version |
|---|---|---|---|
| Nurtec ODTPfizer Laboratories Div Pfizer Inc | What its label approvesAcute treatment of migraine, and prevention of episodic migraineCovers migraine | SupplyPrescription | Label version4 June 2026 |
How it works
Rimegepant blocks the receptor for CGRP, a signaling molecule involved in migraine attacks. The ODT in the product's name is the form: an orally disintegrating tablet, taken with or without food, with one 75 mg strength for both of its uses.
Mechanism of action, Nurtec ODT label
Rimegepant is a calcitonin gene-related peptide receptor antagonist.
What the FDA approved it for
The approved uses, as worded in the label.
- acute treatment of migraine with or without aura in adults
- preventive treatment of episodic migraine in adults Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.
Forms and strengths
The presentations and strengths listed in the label.
- Orally disintegrating tablets: white to off-white, circular, and debossed with the symbol, each containing 75 mg of rimegepant.
- NURTEC ODT orally disintegrating tablets: 75 mg
How the label says it is taken
What the label states about administration. It is not a dosing instruction for any individual.
- Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed.
- The safety of using more than 18 doses in a 30-day period has not been established.
- Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day.
- The maximum dose in a 24-hour period is 75 mg.
- NURTEC ODT can be taken with or without food. Recommended Dosing for Acute Treatment of Migraine The recommended dose of NURTEC ODT is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established. NURTEC ODT can be taken with or without food.
Most common adverse reactions
The adverse reactions the label reports as most common.
- most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo).
- most common adverse reactions (occurring in at least 2% of rimegepant-treated patients and at a frequency of at least 1% higher than placebo) in Study 2 were nausea (2.7% in patients who received rimegepant compared with 0.8% of patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received rimegepant compared with 0.8% of patients who received placebo).
Warnings and precautions
The warnings and precautions section of the label.
- Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration.
- Hypertension: New-onset or worsening of pre-existing hypertension may occur.
- Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur. Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, dyspnea, and rash, have occurred in patients treated with NURTEC ODT. Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred.
Contraindications
Situations in which the label states the medication must not be used.
- NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.
- Reactions have included anaphylaxis and delayed serious hypersensitivity.
Drug interactions
Interactions the label singles out.
- Strong CYP3A4 Inhibitors: Avoid concomitant administration.
- Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor.
- Strong and Moderate CYP3A Inducers: Avoid concomitant administration.
- Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. CYP3A4 Inhibitors Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4.
Pregnancy and breastfeeding
The opening of the pregnancy section of the label. The full section is longer and is in the source document.
Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to NURTEC ODT during pregnancy. For more information, healthcare providers or patients are encouraged to contact: 1-877-366-0324, email crgnurtecpregnancyregistry@thermofisher.com, or visit nurtecpregnancyregistry.com. Risk Summary There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women.
Generic or brand
There is no FDA-approved generic rimegepant: the register lists the brand application only.
The FDA label database lists no approved generic application for this ingredient.
What affects the cost
Nurtec ODT is brand-only, and the acquisition cost below reflects a brand price per tablet. What a person pays depends on insurance coverage. This site sells nothing and links to no sellers.
What pharmacies pay for it
These are acquisition costs: what pharmacies in the United States pay on average to buy the medication, published weekly by the Centers for Medicare and Medicaid Services. They are not retail prices and not what a person pays at the counter, which depends on insurance, pharmacy and discount programs. They are useful as an objective floor and for seeing how far a brand sits above its generic.
| Measured | Brand |
|---|---|
| per tablet, capsule or pen | Brand$128.75 (range $128.66 to $128.75, 34 listings) |
Median of 34 listings. Effective dates 2026-01-01 to 2026-08-19, file dated 2026-08-26.
Compared with other medications
What the labels do not do is compare one medication against another. These pages put two of them side by side.
Common questions
- Is Nurtec for stopping a migraine or preventing one?
- Both, and that is what makes its label unusual. For acute treatment the label says 75 mg taken as needed; for preventive treatment of episodic migraine, 75 mg every other day. It also notes that the safety of using more than 18 doses in a 30-day period has not been established.
- How is Nurtec different from a triptan like Imitrex?
- Different classes with very different contraindication lists. Nurtec is a CGRP receptor antagonist whose label lists one contraindication: hypersensitivity to the product. The Imitrex label lists a series of cardiovascular contraindications, from coronary artery disease to uncontrolled hypertension. The comparison page reads both documents side by side.
- Does Nurtec have a boxed warning?
- No. No label in this category carries a boxed warning; Nurtec's strongest stated risk is hypersensitivity reactions, including anaphylaxis and delayed serious hypersensitivity, quoted on this page.
Other medications under migraine
Whether each one carries an FDA approval for this use is marked on its page and in this list.
Sources
Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.
FDA prescribing information for Nurtec ODT
Pfizer Laboratories Div Pfizer Inc. Label version 32, effective 4 June 2026.
Each stripe is one section of the label, each division in a stripe one entry in that section.
Page last updated 29 August 2026
Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.